GlassScriptPhysician profile
Gary W Davis
NPI 1952495038
$3,385.02
in general payments reported to CMS, 2019-2025
39 companies · $879 in 2025
The $879 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $676 · 2020: $94.56 · 2021: $246 · 2022: $208 · 2023: $456 · 2024: $825 · 2025: $879.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,159.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $543.84 | 2019-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $481.58 | 2021-2025 | Vraylar |
| Novo Nordisk INC | $327.69 | 2019-2025 | Ozempic, Rybelsus |
| Phathom Pharmaceuticals, INC. | $229.98 | 2024-2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $222.13 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.81 | 2019-2025 | Jardiance, Tradjenta |
| Glaxosmithkline, LLC. | $153.40 | 2019-2023 | Shingrix, Trelegy Ellipta, Arexvy |
| Novartis Pharmaceuticals Corporation | $139.14 | 2019-2023 | |
| Pfizer INC. | $124.41 | 2019-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $84.25 | 2022 | |
| Astellas Pharma US INC | $75.81 | 2019 | |
| Lilly USA, LLC | $64.66 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Sanofi-Aventis U.S. LLC | $62.87 | 2021 | |
| Bausch Health US, LLC | $56.61 | 2025 | Aplenzin, Wellbutrin |
| Exact Sciences Corporation | $55.98 | 2023-2024 | Cologuard Collection Kit |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.